SFDA Grants Approval For Innovative Diagnostic Devices Measuring Antipsychotic Drug Levels In Blood

The Saudi Food and Drug Authority (SFDA) has granted marketing authorization for advanced in vitro diagnostic devices. These devices use biotechnology to accurately measure antipsychotic medication levels in the blood, including Quetiapine, Olanzapine, Aripiprazole, Clozapine, and Risperidone. Saudi Arabia is among the first nations to approve such technology, highlighting its commitment to innovative healthcare solutions.

The SFDA's decision followed a thorough scientific evaluation process. This included reviewing technical and clinical documentation and trial reports under expert supervision. The aim was to ensure the safety and effectiveness of these devices. By doing so, the SFDA supports treatment plans for schizophrenia, manic episodes, and bipolar disorder-related depression.

These diagnostic tools empower doctors by providing precise measurements of drug levels in patients' blood. This capability helps monitor adherence to treatment plans and allows for dosage adjustments when necessary. Such precision aims to achieve an optimal therapeutic balance, maximizing effectiveness while minimizing side effects.

The technology behind these devices involves nanoparticle agglutination assays. Nanoparticles bind with drug-specific antibodies, and their accumulation is measured using a spectrophotometer. This method ensures accurate readings of drug concentrations in the bloodstream, enhancing treatment success with precision and safety.

This initiative aligns with the SFDA's dedication to supporting the National Biotechnology Strategy. It also contributes to the Health Sector Transformation Program under Saudi Vision 2030. The SFDA plays a crucial role in fostering innovation by providing a regulatory environment that encourages reliable healthcare solutions following global best practices.

With inputs from SPA